Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain

What Was Tested

The paper reports a study of Methylene blue (non-peptide stack partner), published as a randomized controlled trial.

Purpose To investigate the sustained-attention and memory-enhancing neural correlates of the oral administration of methylene blue in the healthy human brain.

Cerebrovascular reactivity effects were also measured with the carbon dioxide challenge, in which a 2 × 2 repeated-measures analysis of variance was performed with a drug (methylene blue vs placebo) and time (before vs after administration of the drug) as factors to assess drug × time between group interactions.

Why It Was Studied

Materials and Methods The institutional review board approved this prospective, HIPAA-compliant, randomized, double-blinded, placebo-controlled clinical trial, and all patients provided informed consent.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

Twenty-six subjects (age range, 22-62 years) were enrolled.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Methylene blue (non-peptide stack partner) group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Methylene blue (non-peptide stack partner), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Methylene blue (non-peptide stack partner) could be set against what happens without it.

What Was Measured

The subject headings attached to it are Attention, Enzyme Inhibitors, Healthy Volunteers, Image Processing, Computer-Assisted, Magnetic Resonance Imaging, Memory, Short-Term and Methylene Blue.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Methylene blue (non-peptide stack partner).

The publication is from 2016 (Radiology), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.